Clinical significance of cytogenetic abnormalities in uterine myomas.
OBJECTIVE
To investigate the clinical characteristics of uterine myomas with cytogenetic rearrangements.


METHODS
Comparative study of myomas with normal and abnormal karyotype.


METHODS
University hospital.


METHODS
Premenopausal, GnRH-agonist (GnRH-a) treated and menopausal patients.


METHODS
Myomectomy or hysterectomy.


METHODS
Karyotype analysis and clinical characteristics.


RESULTS
Clonal abnormalities occurred in 29% of uterine myomas but were not related to the age of the patient or, in untreated menopausal patients, to the size of the myoma. In GnRH-a treated and menopausal women, 48% of the myomas larger than 4 cm were associated with clonal abnormalities. Submucous myomas had significantly fewer clonal abnormalities (12%) than subserosal (29%) or intramural myomas (35%).


CONCLUSIONS
The data support the hypothesis that cytogenetic rearrangements in uterine myomas are associated with loss of steroid hormones dependency and alter the growth potential of the tumor.
Brosens
I
I
University Hospital Gasthuisberg, Leuven, Belgium.
Deprest
J
J
Dal Cin
P
P
Van den Berghe
H
H
D000328:Adult; D000367:Age Factors; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D002869:Chromosome Aberrations / Q000453:epidemiology* / Q000235:genetics / Q000473:pathology; D025063:Chromosome Disorders; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007621:Karyotyping; D018231:Leiomyomatosis / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D008875:Middle Aged; D015995:Prevalence; D012189:Retrospective Studies; D017329:Triptorelin Pamoate / Q000627:therapeutic use; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology
D018931:Antineoplastic Agents, Hormonal; D017329:Triptorelin Pamoate